Walgreens Pulls 7,500 Pharmacies Out Of Play For Future Network Contracts With CVS Caremark
This article was originally published in The Pink Sheet Daily
Executive Summary
Walgreens cites drug plan designs, lack of information and reimbursement rates in saying it will not participate in new or renewed prescription drug plan contracts with the PBM.
You may also be interested in...
Express Scripts Dispute With Walgreens Spotlights PBMs’ Thirst For Deeper Discounts
The contracting dispute between the drug chain and PBM may also presage tougher negotiations ahead for biopharmaceutical companies, particularly if Express Scripts is successful in its bid to acquire rival PBM Medco.
Coverage, Courts And Congress: News In Brief
Congress again seeks to restrict reverse settlements: Sen. Herb Kohl, D-Wis., proposed an amendment to a tax bill that would amend the Federal Trade Commission Act so that agreements between brand and generic companies to settle patent infringement claims are presumed to have anticompetitive effects if the ANDA filer receives anything of value and agrees to limit or forgo research, development or sales of its product. The presumption shall not apply if the parties "demonstrate by clear and convincing evidence that the precompetitive benefits of the agreement outweigh the anticompetitive effects of the agreement." Kohl introduced the amendment, SA 4332, on June 9 for inclusion in the American Jobs and Closing Tax Loopholes Act, H.R. 4213. Legislators had previously pushed for a similar amendment to render such deals illegal in the health care reform bill (1"The Pink Sheet," March 22, 2010)
Coverage, Courts And Congress: News In Brief
Congress again seeks to restrict reverse settlements: Sen. Herb Kohl, D-Wis., proposed an amendment to a tax bill that would amend the Federal Trade Commission Act so that agreements between brand and generic companies to settle patent infringement claims are presumed to have anticompetitive effects if the ANDA filer receives anything of value and agrees to limit or forgo research, development or sales of its product. The presumption shall not apply if the parties "demonstrate by clear and convincing evidence that the precompetitive benefits of the agreement outweigh the anticompetitive effects of the agreement." Kohl introduced the amendment, SA 4332, on June 9 for inclusion in the American Jobs and Closing Tax Loopholes Act, H.R. 4213. Legislators had previously pushed for a similar amendment to render such deals illegal in the health care reform bill (1"The Pink Sheet," March 22, 2010)